Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boehringer’s Afatinib Buoyed By Priority Review In Bid For Role In EGFR-Positive Lung Cancer

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA accepts afatinib – among Boehringer’s first cancer drugs – in first-line EGFR-mutation positive non-small cell lung cancer. Filing is supported by LUX-Lung 3 study, in which the drug showed a 4.2 month progression-free survival benefit over what some describe as the most effective chemo doublet available.

You may also be interested in...



Astellas Files Personalized Tarceva In First-line Lung Cancer With FDA

If successful, filing in EGFR-positive patients could give Roche/Astellas’ Tarceva a commercial boost, broadening erlotinib’s role in non-small-cell lung cancer.

Boehringer Ingelheim Shrugs Off Patent Cliff, Returns To Sales Growth

Germany's Boehringer Ingelheim returns to sales growth and looks to Phase III hepatitis C and oncology products to provide long-term growth.

Rare Disease Roundtable: Dealing With Pricing Pressure

Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel